scholarly journals New Insights on OX40 in the Control of T Cell Immunity and Immune Tolerance In Vivo

2011 ◽  
Vol 188 (2) ◽  
pp. 892-901 ◽  
Author(s):  
Xiang Xiao ◽  
Weihua Gong ◽  
Gulcin Demirci ◽  
Wentao Liu ◽  
Silvia Spoerl ◽  
...  
1988 ◽  
Vol 19 (1) ◽  
pp. 41-47
Author(s):  
K. Mizoguchi ◽  
K. Isobe ◽  
T. Yoshida ◽  
T. Iwamoto ◽  
T. Hasegawa ◽  
...  

2002 ◽  
Vol 196 (10) ◽  
pp. 1277-1290 ◽  
Author(s):  
Ryohei F. Tsuji ◽  
Marian Szczepanik ◽  
Ivana Kawikova ◽  
Vipin Paliwal ◽  
Regis A. Campos ◽  
...  

Contact sensitivity (CS) is a classic example of in vivo T cell immunity in which skin sensitization with reactive hapten leads to immunized T cells, which are then recruited locally to mediate antigen-specific inflammation after subsequent skin challenge. We have previously shown that T cell recruitment in CS is triggered by local activation of complement, which generates C5a that triggers C5a receptors most likely on mast cells. Here, we show that B-1 cell–derived antihapten IgM antibodies generated within 1 day (d) of immunization combine with local challenge antigen to activate complement to recruit the T cells. These findings overturn three widely accepted immune response paradigms by showing that (a) specific IgM antibodies are required to initiate CS, which is a classical model of T cell immunity thought exclusively due to T cells, (b) CS priming induces production of specific IgM antibodies within 1 d, although primary antibody responses typically begin by day 4, and (c) B-1 cells produce the 1-d IgM response to CS priming, although these cells generally are thought to be nonresponsive to antigenic stimulation. Coupled with previous evidence, our findings indicate that the elicitation of CS is initiated by rapidly formed IgM antibodies. The IgM and challenge antigen likely form local complexes that activate complement, generating C5a, leading to local vascular activation to recruit the antigen-primed effector T cells that mediate the CS response.


Immunity ◽  
1994 ◽  
Vol 1 (4) ◽  
pp. 327-339 ◽  
Author(s):  
Elizabeth R. Kearney ◽  
Kathryn A. Pape ◽  
Dennis Y. Loh ◽  
Marc K. Jenkins

2013 ◽  
Vol 191 (4) ◽  
pp. 1686-1691 ◽  
Author(s):  
Govindarajan Thangavelu ◽  
Ronald G. Gill ◽  
Louis Boon ◽  
Kristofor K. Ellestad ◽  
Colin C. Anderson

2005 ◽  
Vol 201 (4) ◽  
pp. 567-577 ◽  
Author(s):  
Jianuo Liu ◽  
Takashi Miwa ◽  
Brendan Hilliard ◽  
Youhai Chen ◽  
John D. Lambris ◽  
...  

Decay-accelerating factor ([DAF] CD55) is a glycosylphosphatidylinositol-anchored membrane inhibitor of complement with broad clinical relevance. Here, we establish an additional and unexpected role for DAF in the suppression of adaptive immune responses in vivo. In both C57BL/6 and BALB/c mice, deficiency of the Daf1 gene, which encodes the murine homologue of human DAF, significantly enhanced T cell responses to active immunization. This phenotype was characterized by hypersecretion of interferon (IFN)-γ and interleukin (IL)-2, as well as down-regulation of the inhibitory cytokine IL-10 during antigen restimulation of lymphocytes in vitro. Compared with wild-type mice, Daf1−/− mice also displayed markedly exacerbated disease progression and pathology in a T cell–dependent experimental autoimmune encephalomyelitis (EAE) model. However, disabling the complement system in Daf1−/− mice normalized T cell secretion of IFN-γ and IL-2 and attenuated disease severity in the EAE model. These findings establish a critical link between complement and T cell immunity and have implications for the role of DAF and complement in organ transplantation, tumor evasion, and vaccine development.


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17069-17069
Author(s):  
K. Kosmatopoulos ◽  
E. Bolonaki ◽  
D. Aggouraki ◽  
E. Nikoloudi ◽  
P. Kanellou ◽  
...  

17069 Background: BTERT572Y, an optimized cryptic peptide homologous to TERT induces efficient antitumoral T cell cytotoxic immunity but not autoreactivity in vivo in HLA-A*0201 transgenic mice and healthy blood donors and prostate cancer patients (J. Clin. Invest., 2004, 113,425). Moreover, it was well tolerated and effective in eliciting specific T cell immunity in patients (pts) with advanced malignancies (ASCO 2005, abstr 2579). Methods: We evaluated its clinical efficacy, safety and immunogenicity in 13 HLA-A*0201 pts with advanced, stage IIIb (7 pts) and stage IV (6 pts), NSCLC. Three pts were in stable (SD) and ten pts in progressive (PD) disease following prior therapy. The vaccination protocol consisted of two subcutaneous injections of optimized TERT572Y peptide followed by four injections of native TERT572 peptide. Both peptides were emulsified in Montanide ISA51. Results: Eight pts completed the entire vaccination program, 4 discontinued due to PD and 1 is ongoing. The median follow up is 6.5 months (range 2.0–29.9). Three of 10 (30%) pts with prior PD developed SD for 6+, 7+ and 9 months. Overall clinical response was SD in 6 and PD in 7 pts. Median TTP was 8.1 months (range 3.7–9.1) for stage IIIb and 2.3 (range 2–6.9) for stage IV pts. Minimal grade I/II primarily skin toxicity was observed. ELISPot-detected TERT572 specific CD8+ cells were demonstrated in all 7 pts tested. Conclusions: TERT572Y peptide vaccine is well tolerated and effective in eliciting a specific T cell immunity. The disease stabilization observed in 30% of pts with previously progressive disease is very encouraging and deserves further evaluation. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document